Global Influenza Vaccine Market Projected to Reach $13.3B by 2030
Question
Global Influenza Vaccine Market Projected to Reach $13.3B by 2030
Direct answer
Long-term revenue growth for major pharmaceutical players in the vaccine space. — bullish pressure on GSK via TAM expansion for vaccines.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-07
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Global Influenza Vaccine Market Projected to Reach $13.3B by 2030”, revision 1, evidence through 2026-08-07. https://marketontology.com/catalysts/2026-08-07/global-influenza-vaccine-market-projected-to-reach-13-3b-by-2030-d99f7d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GSK | ▲Bull | 1–3 months | TAM expansion for vaccines | 52 |
| SNY | ▲Bull | 1–3 months | TAM expansion for vaccines | 52 |
Global Influenza Vaccine Market Projected to Reach $13.3B by 2030
Long-term revenue growth for major pharmaceutical players in the vaccine space. — bullish pressure on GSK via TAM expansion for vaccines.
Influenza vaccine market projected to reach $13.32B by 2030.
- SourceInfluenza vaccine market projected to reach $13.32B by 2030.
- TransmissionLong-term revenue growth for major pharmaceutical players in the vaccine space.
- SummaryVaccine market to grow 50% by 2030. GSK, Pfizer, and Sanofi are key market players. Aging demographics provide a structural tailwind.
- GSKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GSK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GSK price vs. pre-event level
- GSK volume vs. 20-day average
Global Influenza Vaccine Market Projected to Reach $13.3B by 2030
Long-term revenue growth for major pharmaceutical players in the vaccine space. — bullish pressure on SNY via TAM expansion for vaccines.
Influenza vaccine market projected to reach $13.32B by 2030.
- SourceInfluenza vaccine market projected to reach $13.32B by 2030.
- TransmissionLong-term revenue growth for major pharmaceutical players in the vaccine space.
- SummaryVaccine market to grow 50% by 2030. GSK, Pfizer, and Sanofi are key market players. Aging demographics provide a structural tailwind.
- SNYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- SNY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- SNY price vs. pre-event level
- SNY volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Global Influenza Vaccine Market Report, 2026 Edition · news · 2026-08-07
Related catalysts
- 2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830GSK
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugateGSK HCM+0.14%
- 2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830GSK
- 2026-09-28HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830GSK HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysGSK RHHBY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.